Netilmicin

As an upgraded variety of aminoglycoside antibiotics, netilmicin blocks protein synthesis by inhibiting the 30S subunit of bacterial ribosomes, and exhibits strong bactericidal activity against Gram-negative bacteria and some Gram-positive bacteria. In particular, it remains sensitive to Enterobacteriaceae bacteria and Pseudomonas aeruginosa that are resistant to other aminoglycosides. It is mainly used clinically to treat lower respiratory tract infections, complicated urinary tract infections, sepsis, skin and soft tissue infections, etc. caused by sensitive bacteria, and is suitable for adult and pediatric patients with sensitive bacterial infections. Due to its lower ototoxicity and nephrotoxicity than gentamicin and tobramycin of the same category, it occupies an important position in the empirical treatment of moderate and severe bacterial infections.

The current global market size of aminoglycoside antibiotics is approximately US$2.8 billion, of which netilmicin accounts for approximately 4.2%, with a compound annual growth rate of 2.1% in the past three years. The growth momentum mainly comes from the increased demand for infection prevention and control in primary medical institutions and the supplementary demand for drug-resistant bacteria treatment regimens. In the domestic market, the annual sales of netilmicin preparations are approximately RMB 630 million. As the national centralized procurement gradually expands the coverage of aminoglycoside varieties, the generic drug substitution rate has exceeded 85%, and the upstream API supply has basically achieved localization. Only a small number of high-end preparations still rely on imported APIs.

The original research enterprise of netilmicin is Schering-Plough, and the original research brand name is Netromycin. Its core compound patent expired globally in 1999. The main dosage form approved for the original research product is injection, with specifications including 50mg/2ml and 100mg/2ml. It has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. At present, 12 domestic enterprises have obtained Class A status for their netilmicin APIs through CDE registration, and more than 30 generic varieties of netilmicin injection have been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for netilmicin API, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable reference material support for the whole process of API R&D, quality research and production.